These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
260 related articles for article (PubMed ID: 31346334)
21. The effect of superparamagnetic iron oxide with iRGD peptide on the labeling of pancreatic cancer cells in vitro: a preliminary study. Zuo HD; Yao WW; Chen TW; Zhu J; Zhang JJ; Pu Y; Liu G; Zhang XM Biomed Res Int; 2014; 2014():852352. PubMed ID: 24977163 [TBL] [Abstract][Full Text] [Related]
22. Zerumbone Induces Apoptosis in Breast Cancer Cells by Targeting αvβ3 Integrin upon Co-Administration with TP5-iRGD Peptide. E M Eid E; S Alanazi A; Koosha S; A Alrasheedy A; Azam F; M Taban I; Khalilullah H; Sadiq Al-Qubaisi M; A Alshawsh M Molecules; 2019 Jul; 24(14):. PubMed ID: 31337024 [TBL] [Abstract][Full Text] [Related]
23. A tumor-penetrating peptide modification enhances the antitumor activity of thymosin alpha 1. Lao X; Liu M; Chen J; Zheng H PLoS One; 2013; 8(8):e72242. PubMed ID: 23977262 [TBL] [Abstract][Full Text] [Related]
24. iRGD-targeted delivery of a pro-apoptotic peptide activated by cathepsin B inhibits tumor growth and metastasis in mice. Qifan W; Fen N; Ying X; Xinwei F; Jun D; Ge Z Tumour Biol; 2016 Aug; 37(8):10643-52. PubMed ID: 26867766 [TBL] [Abstract][Full Text] [Related]
25. Enhanced Tumor Targeting and Penetration of Proteolysis-Targeting Chimeras through iRGD Peptide Conjugation: A Strategy for Precise Protein Degradation in Breast Cancer. He S; Fang Y; Wu M; Zhang P; Gao F; Hu H; Sheng C; Dong G J Med Chem; 2023 Dec; 66(24):16828-16842. PubMed ID: 38055861 [TBL] [Abstract][Full Text] [Related]
26. Co-administration of iRGD with peptide HPRP-A1 to improve anticancer activity and membrane penetrability. Hu C; Chen X; Huang Y; Chen Y Sci Rep; 2018 Feb; 8(1):2274. PubMed ID: 29396568 [TBL] [Abstract][Full Text] [Related]
27. Molecular View on the D'Amore VM; Donati G; Lenci E; Ludwig BS; Kossatz S; Baiula M; Trabocchi A; Kessler H; Di Leva FS; Marinelli L J Chem Inf Model; 2023 Oct; 63(20):6302-6315. PubMed ID: 37788340 [TBL] [Abstract][Full Text] [Related]
28. A comprehensive study of iRGD-modified liposomes with improved chemotherapeutic efficacy on B16 melanoma. Dai W; Fan Y; Zhang H; Wang X; Zhang Q; Wang X Drug Deliv; 2015 Jan; 22(1):10-20. PubMed ID: 24735248 [TBL] [Abstract][Full Text] [Related]
29. Modification of IL-24 by tumor penetrating peptide iRGD enhanced its antitumor efficacy against non-small cell lung cancer. Yang J; Yang J; Wei Y; Yin H; Fang L; Chai D; Li H; Li H; Zhang Q; Zheng J Int Immunopharmacol; 2019 May; 70():125-134. PubMed ID: 30798161 [TBL] [Abstract][Full Text] [Related]
30. Tumor-penetrating peptide fused EGFR single-domain antibody enhances cancer drug penetration into 3D multicellular spheroids and facilitates effective gastric cancer therapy. Sha H; Zou Z; Xin K; Bian X; Cai X; Lu W; Chen J; Chen G; Huang L; Blair AM; Cao P; Liu B J Control Release; 2015 Feb; 200():188-200. PubMed ID: 25553823 [TBL] [Abstract][Full Text] [Related]
31. Co-administration of kla-TAT peptide and iRGD to enhance the permeability on A549 3D multiple sphere cells and accumulation on xenograft mice. Hu C; Chen X; Huang Y; Chen Y Chem Biol Drug Des; 2018 Aug; 92(2):1567-1575. PubMed ID: 29722179 [TBL] [Abstract][Full Text] [Related]
32. iRGD-mediated core-shell nanoparticles loading carmustine and O Liu C; Yao S; Li X; Wang F; Jiang Y J Drug Target; 2017 Mar; 25(3):235-246. PubMed ID: 27646474 [TBL] [Abstract][Full Text] [Related]
33. Combination of NRP1-mediated iRGD with 5-fluorouracil suppresses proliferation, migration and invasion of gastric cancer cells. Zhang L; Xing Y; Gao Q; Sun X; Zhang D; Cao G Biomed Pharmacother; 2017 Sep; 93():1136-1143. PubMed ID: 28738522 [TBL] [Abstract][Full Text] [Related]
34. A Lipopeptide-Based αvβ₃ Integrin-Targeted Ultrasound Contrast Agent for Molecular Imaging of Tumor Angiogenesis. Yan F; Xu X; Chen Y; Deng Z; Liu H; Xu J; Zhou J; Tan G; Wu J; Zheng H Ultrasound Med Biol; 2015 Oct; 41(10):2765-73. PubMed ID: 26166460 [TBL] [Abstract][Full Text] [Related]
35. Design of an Amphiphilic iRGD Peptide and Self-Assembling Nanovesicles for Improving Tumor Accumulation and Penetration and the Photodynamic Efficacy of the Photosensitizer. Jiang Y; Pang X; Liu R; Xiao Q; Wang P; Leung AW; Luan Y; Xu C ACS Appl Mater Interfaces; 2018 Sep; 10(37):31674-31685. PubMed ID: 30133254 [TBL] [Abstract][Full Text] [Related]
36. Coadministration of iRGD with Multistage Responsive Nanoparticles Enhanced Tumor Targeting and Penetration Abilities for Breast Cancer Therapy. Hu C; Yang X; Liu R; Ruan S; Zhou Y; Xiao W; Yu W; Yang C; Gao H ACS Appl Mater Interfaces; 2018 Jul; 10(26):22571-22579. PubMed ID: 29878758 [TBL] [Abstract][Full Text] [Related]
37. Design and Function of Engineered Protein Nanocages as a Drug Delivery System for Targeting Pancreatic Cancer Cells via Neuropilin-1. Murata M; Narahara S; Kawano T; Hamano N; Piao JS; Kang JH; Ohuchida K; Murakami T; Hashizume M Mol Pharm; 2015 May; 12(5):1422-30. PubMed ID: 25811429 [TBL] [Abstract][Full Text] [Related]
38. Tumor-penetrating peptide fused to a pro-apoptotic peptide facilitates effective gastric cancer therapy. Huang Y; Li X; Sha H; Zhang L; Bian X; Han X; Liu B Oncol Rep; 2017 Apr; 37(4):2063-2070. PubMed ID: 28260064 [TBL] [Abstract][Full Text] [Related]
39. Homing Peptides for Cancer Therapy. Lingasamy P; Teesalu T Adv Exp Med Biol; 2021; 1295():29-48. PubMed ID: 33543454 [TBL] [Abstract][Full Text] [Related]